Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat

Abstract

Prolonged treatment with the beta(2)-adrenoceptor agonist clenbuterol (1-2 mg. kg body mass(-1). day (-1)) is known to induce the hypertrophy of fast-contracting fibers and the conversion of slow- to fast-contracting fibers. We investigated the effects of administering a lower dose of clenbuterol (250 microgram. kg body mass(-1). day (-1)) on skeletal muscle myosin heavy chain (MyHC) protein isoform content and adenine nucleotide (ATP, ADP, and AMP) concentrations. Male Wistar rats were administered clenbuterol (n = 8) or saline (n = 6) subcutaneously for 8 wk, after which the extensor digitorum longus (EDL) and soleus muscles were removed. We demonstrated an increase of type IIa MyHC protein content in the soleus from approximately 0.5% in controls to approximately 18% after clenbuterol treatment (P < 0.05), which was accompanied by an increase in the total adenine nucleotide pool (TAN; approximately 19%, P < 0.05) and energy charge [E-C = (ATP + 0.5 ADP)/(ATP + ADP + AMP); approximately 4%; P < 0.05]. In the EDL, a reduction in the content of the less prevalent type I MyHC protein from approximately 3% in controls to 0% after clenbuterol treatment (P < 0.05) occurred without any alterations in TAN and E-C. These findings demonstrate that the phenotypic changes previously observed in slow muscle after clenbuterol administration at 1-2 mg. kg body mass(-1). day(-1) are also observed at a substantially lower dose and are paralleled by concomitant changes in cellular energy metabolism.

cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration

“…Genetic inhibition of CREB activity in differentiated muscle leads to defects in myofiber survival but not alterations in muscle fiber type (19). Finally, a large body of data from humans and model organisms shows that chronic stimulation of ␤ 2 -AR signaling causes shifts toward faster, not slower, myofiber phenotypes (14,47,55,150,180,183,252).…”

Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats

“…Notably, myostatin does not exert its action through NF-κB (25). β2-adrenergic agonists are potent muscle growth promoters in many animal species (26,27), resulting in skeletal muscle hypertrophy (28)(29)(30)(31). Formoterol is one of these compounds with important anti-cachectic effects in animal models.…”

Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity

“…Treatment with β 2 -adrenergic agonists results in skeletal muscle hypertrophy (11)(12)(13)(14), while they cause a reduction in the body fat content (15,16). Formoterol, one of these compounds, is a highly potent β 2 -adrenoceptor-selective agonist which combines the clinical advantages of rapid onset of action with duration of action.…”